# Source check — claim 45fa5df1cdb7decff866f9ab5863bb285311315fa9412e21ffee2e69b39a3fd6

Claim: Abstract extract PMID 34302589 ("A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer."):  Key fragments: treated HER2+ MBC to evaluate efficacy, toxicity, and genomic alterations driving therapeutic response. After a run-in phase for eribulin dosing, tw | correction. Eribulin-HP had manageable toxicity and modest clinical activity in patients without prior pertuzumab exposure. This study provides a p | ations may predict for therapy response/resistance, as we work to individualize choices in a quickly evolving HER2+ MBC treatment landscape. www.clini Abstract-only SHA-256 TITLE+PMID+ABSTRACT=a8af57e11a9fba465f8262b70db40a476f54b3ff06c19022734f6d0db089442a. Not treatment advice.
Source: PMID 34302589 (https://pubmed.ncbi.nlm.nih.gov/34302589/)
Checked: 2026-09-23T00:41:34.169Z

## Method
1. Fetched abstract via NCBI efetch (rettype=abstract).
2. Deterministic numeric check: every number in the claim searched verbatim in the source text.
3. Semantic check: qwen3:8b (temp 0), schema-constrained verdict.

## Findings
Numeric tokens missing from source: 256, 57, 465, 8262, 70, 40, 476, 19022734, 089442
Model verdict: supports
Reasoning: The source text supports the claim. The claim mentions that the study evaluated efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with HER2+ metastatic breast cancer. The source text confirms this by stating, 'We conducted a phase II study of eribulin mesylate, which extends survival in MBC, with HP in patients with previously treated HER2+ MBC to evaluate efficacy, toxicity, and genomic alterations driving therapeutic response.' Additionally, the text discusses the toxicity and clinical activity of eribulin-HP and the role of genomic alterations in predicting therapy response/resistance, which aligns with the claim.
Final result: inconclusive (confidence 4000 bps)

Limitations: abstract-level check only; full text not reviewed.
Source sha256: d274b1b9fe056bae7d27f2d1abb881298611ee6d6a2834f40b46f7f2faf3af59